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ABSTRACT 
 
 
 The generation of induced pluripotent stem cells (iPSCs) through the use of small 
molecule compounds has evolved as a potential cellular reprogramming strategy. 
Individually, specific small molecule compounds have previously been shown to replace 
reprogramming transcription factors or enhance the efficiency of cellular reprogramming. 
More recently, a combination of small molecule compounds can replace all of the 
reprogramming factors. In this review, we describe in detail the generation of chemically 
induced pluripotent stem cells using small molecule inhibitors and activators that target 
either downstream protein kinases or modify chromatin structure to promote somatic cell 
reprogramming. In addition, epigenetic modulating small molecule compounds that 
enhance cellular reprogramming and functionally replace some reprogramming factors 
are discussed. 
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CHAPTER 1.    INTRODUCTION 
 
 
Since Yamanaka and colleagues reported the generation of induced pluripotent 
stem cells (iPSCs) from mouse embryonic fibroblasts (MEFs) there has been a growing 
amount of research in stem cells particularly concerning cellular reprogramming to 
generate them and control their cell fate. The virus-mediated overexpression of four 
specific transcription factors (Oct3/4, Sox2, Klf4, and c-Myc (OSKM)) reprograms 
mouse embryonic fibroblasts into pluripotent cells that share similar characteristics with 
embryonic stem cells (ESCs) including gene expression, epigenetic characteristics, and 
developmental potential (Takahashi and Yamanaka 2006, Takahashi, Tanabe et al. 2007). 
Subsequently, human adult fibroblasts were reprogrammed into iPSCs by overexpressing 
the same four factors, or a combination of other factors including Nanog and Lin28 (Yu, 
Vodyanik et al. 2007). Human iPSCs (hiPSCs) derived from fibroblasts share 
characteristics with human ESCs (hESCs), including the ability to differentiate into cell 
types of all three germ layers. This is thought to occur through the restoration of the 
transcriptional circuitry and epigenetic factors involved in pluripotency. iPSCs also 
closely resemble PSCs in their biological properties and epigenetic characteristics 
(Jaenisch and Young 2008, Yamanaka and Blau 2010, Yamanaka 2012). 
  
Interestingly, the four specific transcription factors inducing cellular 
reprogramming to pluripotency have been shown to each have a distinct role. The 
molecular events leading to the induction of pluripotency has recently been reviewed 
(Kulcenty, Wroblewska et al. 2015). Exogenous Oct3/4 and Sox2 are required for mature 
iPSC production, while exogenous Klf4 and c-Myc enhance reprogramming efficiency 
(Takahashi, Tanabe et al. 2007). c-Myc targets have been shown to regulate cellular 
proliferation, metabolism, and biosynthetic pathways, while Oct4, Klf4 and Sox2 targets 
have been shown to regulate the transcriptional and developmental regulators of 
pluripotency (Chen, Xu et al. 2008, Kim, Chu et al. 2008, Sridharan, Tchieu et al. 2009, 
Kim, Woo et al. 2010). During the initial phase of reprogramming, c-Myc activates 
pluripotency markers after induction of OSKM into target cells (Polo, Anderssen et al. 
2012). c-Myc couples with histone acetyltransferase complexes and promotes histone 
acetylation, leading to the binding of exogenous Oct3/4 and Sox2 to DNA (Soufi, 
Donahue et al. 2012). The transcription factor Klf4 has opposing roles. During the initial 
phase of reprogramming, Klf4 inhibits the expression of reprogramming genes, yet 
during the later phase of reprogramming Klf4 activates expression of Nanog in addition 
to other stem cell genes by repressing p53 (Lin, Chao et al. 2005, Rowland, Bernards et 
al. 2005). Sox2 is expressed during the entire reprogramming process, while Oct3/4 
activation during the later stages is essential to generate fully reprogrammed, mature 
iPSCs (Chen, Vega et al. 2008, Samavarchi-Tehrani, Golipour et al. 2010, Polo, 
Anderssen et al. 2012). More specifically, Oct3/4 recruits chromatin-remodeling 
complexes to regulatory regions, (Singhal, Graumann et al. 2010) in addition to binding 
to heterochromatin (Soufi, Donahue et al. 2012). 
  
Although iPSCs have been key investigational tools in stem cell research and are 
emerging as a focus in drug discovery, clinical application has been limited by the use of 
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viral delivery systems for the transcription factors and the introduction of oncogenic       
c-Myc, both of which contribute to iPSC tumorigenicity. Most hiPSCs are made using 
retroviruses or lentiviruses, which have the capacity to integrate the reprogramming 
transcription factors into host genomes, increasing the potential for tumor formation. 
Viral integration may be deleterious because once integrated, the provirus is replicated, 
along with the host-cell DNA, and genetically incorporated into the host genome (Okita, 
Ichisaka et al. 2007, Zhao, Zhang et al. 2011, Polo, Anderssen et al. 2012). In addition, 
viral integration may affect the differentiation of iPSCs. Direct delivery and transient 
expression of the reprogramming factors using adenovirus vectors or plasmids are two 
methods that have been shown to avoid genomic alterations of iPSCs (Okita, Nakagawa 
et al. 2008, Stadtfeld, Nagaya et al. 2008, Okita, Matsumura et al. 2011). RNAs have also 
been utilized to generate iPSCs while reducing the risk of genomic integration of 
oncogenes, and increasing reprogramming efficiency (Warren, Manos et al. 2010, 
Anokye-Danso, Trivedi et al. 2011, Li, Yang et al. 2011, Subramanyam, Lamouille et al. 
2011, Yang, Li et al. 2011, Bao, Zhu et al. 2013, Rabinovich and Weissman 2013, Wang 
and Na 2013). In addition, protein-induced pluripotent stem cells have been reported 
(Kim, Kim et al. 2009, Zhou, Wu et al. 2009) and previously reviewed, (Higuchi, Ling et 
al. 2015) and whole cell extracts have also been used to achieve complete reprogramming 
into iPSCs without the expression of transgenes (Cho, Lee et al. 2010). However, these 
transient expression methods are extremely inefficient. The efficiency of protein-iPSC 
generation, for example, is approximately 0.001%, further suggesting the need for a 
better reprogramming method (Higuchi, Ling et al. 2015). 
 
Small molecules that target a specific signaling pathway, epigenetic process or 
other cellular processes have the ability to reprogram somatic cells into iPSCs without the 
use of heterologous genetic material or proteins (Huangfu, Maehr et al. 2008, Feng, Ng et 
al. 2009, Anastasia, Pelissero et al. 2010, Firestone and Chen 2010, Li and Ding 2010, 
Lukaszewicz, McMillan et al. 2010, Zhang 2010, Zhu, Li et al. 2010, Zhu, Wei et al. 
2011, Li, Jiang et al. 2012, Gross, Sgodda et al. 2013, Hou, Li et al. 2013, Lu, Kong et al. 
2013, Wu, Pandian et al. 2013, Xie, Cao et al. 2014). Substantial progress has been made 
in discovering small molecule compounds that maintain pluripotency by functionally 
replacing one of the distinct reprogramming transcription factors. These molecules can 
also enhance the efficiency of reprogramming and accelerate the reprogramming process. 
Small molecule compounds can directly regulate the expression of pluripotent 
transcription factor genes, resulting in the reprogramming of somatic cells into iPSCs 
(Huangfu, Osafune et al. 2008, Shi, Desponts et al. 2008, Ichida, Blanchard et al. 2009, 
Li, Zhou et al. 2009, Lin, Ambasudhan et al. 2009, Lyssiotis, Foreman et al. 2009, 
Maherali and Hochedlinger 2009, Esteban, Wang et al. 2010) (Table 1-1). 
  
The first study reporting to reprogram mouse somatic cells to pluripotency 
without the use of genetic manipulation used a combination of seven small molecule 
compounds (Hou, Li et al. 2013). Ultimately, one of the goals in cellular reprogramming 
to hiPSCs is to have small molecules substitute for all four distinct transcription factors. 
In this review, we highlight the major classes of small molecule modulators of key 
signaling pathways and small molecule epigenetic modulators, used to date, to enhance 
the efficiency of cellular reprogramming, in addition to their prospective opportunities.
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Table 1-1. Small molecules promoting somatic cell reprogramming 
 
Small Molecules Function Effects on Reprogramming Host 
Animal 
Reference 
TGFβ receptor inhibitors     
616452 (E-616452, 
RepSox) 
TGF-β inhibitor (ALK 
inhibitor II) 
can replace Sox2 mouse, 
human 
Attisano & Wrana 2002; 
Ichida, Blanchard 2009 
A83-01 TGF-β inhibitor reprogramming enhancer mouse, 
human 
Zhu, Li 2010; Yuan, 
Wan 2011 
LY-364947 TGF-β inhibitor can replace Sox2 mouse Ichida, Blanchard 2009; 
Staerk, Lyssiotis 2011 
SB431542 TGF-β inhibitor reprogramming enhancer mouse, 
human 
Li, Zhou 2009 
GSK-3β inhibitors     
CHIR99021 (CHIR) GSK-3β inhibitor & Wnt 
signaling pathway activator 
can replace Sox2 mouse, 
human 
Li, Zhou 2009;Li, Zhang 
2011 
Kenpaullone GSK-3/CDKs inhibitor can replace Klf4 mouse Lyssiotis, Foreman 2009 
Compound B6 GSK-3β inhibitor  reprogramming enhancer mouse Li, Rana 2012 
Lithium Chloride (LiCl) GSK-3β inhibitor, LSD1 
inhibitor 
reprogramming enhancer mouse, 
human 
Wang, Xu 2011 
MEK inhibitor     
PD0325901 (PD) MEK inhibitor reprogramming enhancer mouse, 
human 
Shi, Do 2008 
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Table 1-1.  Continued 
 
Small Molecules Function Effects on Reprogramming Host 
Animal 
Reference 
cAMP agonists     
Forskolin (FSK) Adenylyl cyclase agonist, 
causes an increase in cAMP 
levels 
can replace Oct4 in 
combination with 2-Me-5HT & 
D4476 
mouse Hou 2013 
Prostaglandin E2 EP4 (Prostaglandin E receptor 
4) agonist, increases cAMP 
levels 
reprogramming enhancer mouse Hou 2013 
Rolipram PDE4 antagonist, causes an 
increase in cAMP levels  
reprogramming enhancer mouse Hou 2013 
8-Br-cAMP PKA activator reprogramming enhancer human Jung, Kim 2014 
Sonic hedgehog signaling 
activators 
    
Oxysterol (25-OHChl) SMO agonist can replace Sox2, Klf4, c-Myc mouse Moon, Heo 2011 
Purmorphamine SMO agonist can replace Sox2, Klf4, c-Myc mouse Moon, Heo 2011 
Sonic hedgehog (Shh) Sonic hedgehog signaling can replace Sox2, Klf4, c-Myc mouse Moon, Heo 2011 
Histone deacetylase 
(HDAC) inhibitors 
    
Sodium butyrate (NaB) HDAC inhibitor reprogramming enhancer mouse, 
human 
Mali P, 2010 
Valproic acid (VPA) HDAC inhibitor reprogramming enhancer; can 
replace c-Myc/Klf4 in human 
fibroblasts 
mouse, 
human 
Huangfu D, Maehr R, 
2008; Huangfu D, 
Osafune K, 2008; Li Y 
2011 
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Table 1-1.  Continued 
 
Small Molecules Function Effects on Reprogramming Host 
Animal 
Reference 
Suberoylanilide 
hydroxamic acid (SAHA) 
HDAC inhibitor reprogramming enhancer mouse Huangfu D, Maehr R, 
2008 
Trichostain A (TSA) HDAC inhibitor reprogramming enhancer mouse Huangfu D, Maehr R, 
2008 
Histone demethylase 
(HDM) inhibitor 
    
Tranylcypromine (Parnate)  H3K4 demethylation inhibitor reprogramming enhancer mouse Li W, Zhou H 2009; Li 
MG 2006 
DNA methyltransferase 
(DNMT) inhibitors 
    
5-Azacytidine (AZA, 5-
aza-CR) 
DNMT inhibitor reprogramming enhancer mouse Mikkelson 2008; Papp, 
Plath 2013 
RG108 DNMT inhibitor can replace Sox2 (with BIX) or 
Oct4 
mouse Shi, Desponts 2008; Li 
W, Ding S. 2010; Li, 
Zhou 2009 
RSC133 DNMT inhibitor/histone 
deacetylase inhibitor 
reprogramming enhancer human Lee J 2012 
Histone 
methyltransferase 
(HMT) inhibitor 
    
BIX-01294 (BIX) G9a HMTase inhibitor reprogramming enhancer; can 
replace Sox2 
mouse Shi, Do 2008 
Src family tyrosine 
kinase inhibitors 
    
Dasatinib Src family tyrosine kinase 
inhibitor 
can replace Sox2 mouse  Staerk, Lyssiotis 2011 
iPY razine (iPY) Src family tyrosine kinase 
inhibitor 
can replace Sox2 mouse  Staerk, Lyssiotis 2011 
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Table 1-1.  Continued 
 
Small Molecules Function Effects on Reprogramming Host 
Animal 
Reference 
Src family tyrosine 
kinase inhibitors cont’d. 
    
PP1 Src family tyrosine kinase 
inhibitor 
can replace Sox2 mouse  Staerk, Lyssiotis 2011 
Miscellaneous     
AMI-5 Protein arginine 
methyltransferase inhibitor 
can replace Sox2, Klf4 (with A-
83-01) 
mouse Yuan, Wan 2011 
D4476 CK1 inhibitor can replace Oct4 with FSK & 
2-Me-5HT 
mouse Hou 2013 
Compound B4 (TGFβ-RI) ALK4 inhibitor reprogramming enhancer mouse Li, Rana 2012 
Compound B10 P38 kinase inhibitor reprogramming enhancer mouse Li, Rana 2012 
Compound B8 inositol triphosphate 3-kinase 
(IP3K) inhibitor 
reprogramming enhancer mouse Li, Rana 2012 
Rapamycin mTOR inhibitor reprogramming enhancer mouse Chen, Shen 2011 
N-oxaloylglycine prolyl-4-hydroxylase inhibitor reprogramming enhancer human Zhu, Li 2010 
Quercetin hypoxia inducible factor (HIF) 
pathway activator 
reprogramming enhancer human Zhu, Li 2010 
Fructose 2,6-bisphosphate phosphofructokinase 1 
activator 
reprogramming enhancer human Zhu, Li 2010 
PS48 (5-(4-Chloro-
phenyl)-3-phenyl-pent-2-
enoic acid) 
3'-phosphoinositide-dependent 
kinase 1 (PDK1) activator 
reprogramming enhancer human Zhu, Li 2010 
2,4-dinitrophenol (DNP) oxidative phosphorylation 
uncoupler 
reprogramming enhancer human Zhu, Li 2010 
TTNPB Retinoic acid receptor ligand reprogramming enhancer mouse Hou 2013 
3-deazaneplanocin 
(DZNep) 
Epigenetic modulator reprogramming enhancer mouse Hou 2013 
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CHAPTER 2.    SMALL MOLECULE COMPOUNDS THAT MODULATE 
CELLULAR PATHWAYS TO PROMOTE IPSC PRODUCTION 
 
 
Several of the cellular pathways deregulated in human cancers are also linked to 
the production of iPSCs, and there is evidence to support the notion that some human 
cancers are a stem cell disease. Three critical signaling pathways involved in the 
chemical reprogramming of stem cells and cancer are TGF-β, Wnt, and 
FGF/MAPK/ERK. TGF-β, Wnt, and FGF/MAPK/ERK signaling critically regulate the 
reprogramming process (Hawkins, Joy et al. 2014), control stem cell differentiation 
(Wang and Chen 2015), and maintain the stem cell state (Dalton 2013). TGF-β signaling 
specifically plays a critical role in regulating pluripotency and differentiation of ESCs 
(Itoh, Watabe et al. 2014). Glycogen synthase kinase 3 (GSK3) interacts with the Wnt 
signaling pathway and helps regulate cell fate determination (McCubrey, Steelman et al. 
2014). GSK inhibitors maintain stem cell pluripotency and help generate iPSCs (Doble 
and Woodgett 2009). These key signaling pathways also have a significant function in 
cancer. Small molecule compounds targeting FGFR is an expanding topic in clinical 
oncology because FGF signaling is involved in many aspects of cancer biology (Heinzle, 
Sutterluty et al. 2011).  Small molecule compounds have also been developed to target 
the TGF-β signaling pathway (Principe, Doll et al. 2014) and the Wnt signaling pathway, 
given the aberrant activation of this pathway in various cancers (Zhang and Hao 2015).  
 
Small molecule compounds capable of modulating cell-cycle signaling pathways 
to promote iPSC production using only a few transcription factors have recently been 
reviewed (Zhang, Yang et al. 2009, Green and Lee 2013). Small molecule inhibitors with 
these effects typically target either downstream protein kinases activated by the 
transcription factor or modify chromatin structure and thus directly affect transcription 
factor function. Specifically, the pharmacological inhibition of three key players, 
including the transforming growth factor (TGF)-β receptor, glycogen synthase kinase 3 
(GSK3)-β and mitogen-activated protein kinase (MAPK), enhances somatic cell 
reprogramming (Sanges and Cosma 2010, Federation, Bradner et al. 2014, Jung, Kim et 
al. 2014). 
 
 
FGF/MAPK/ERK Signaling Pathway 
 
The MEK-MAPK/ERK (extracellular signal-regulated kinases) pathway is a 
protein kinase cascade that controls many cellular processes including induction of 
pluripotency (Sanges and Cosma 2010). MAPK regulates several transcription factors 
including c-Myc. ERK signaling has been shown to induce differentiation of pluripotent 
ESCs to a committed lineage through FGF stimulation (Kunath, Saba-El-Leil et al. 2007).  
Conversely, inhibition of the ERK pathway enhances reprogramming efficiency of mouse 
somatic cells to a pluripotent state. Indeed, inhibiting ERK1/2 with PD98059 
(MAPK/ERK inhibitor) treatment results in increased Oct4-expression (Buehr and Smith 
2003). Fibroblast growth factors (FGFs) play a key role in the proliferation and 
differentiation of a variety of cells, and can activate the MAPK/ERK pathway through 
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MEK (MAPK/ERK kinase) activation. PD0325901 (PD) (1), a small molecule MEK 
(MAP3 kinase) inhibitor, promotes the efficiency of mouse and human iPSC (miPSC, 
hiPSC) reprogramming and late somatic cell reprogramming (after Oct4 activation). 
PD0325901 also inhibits the growth of non-iPSC colonies and supports the growth of 
reprogrammed iPSCs (Shi, Do et al. 2008, Silva, Barrandon et al. 2008) (Figure 2-1). 
 
 
TGF-β Signaling Pathway 
 
Morphogens relating to TGF-β, including the bone morphogenetic proteins 
(BMPs), regulate stem cell fate commitment (Varga and Wrana 2005). BMP signaling, in 
conjunction with leukemia inhibiting factor (LIF) signaling, maintains pluripotency in 
mESCs (Ying, Nichols et al. 2003), whereas TGF-β signaling maintains pluripotency in 
hESCs and mouse stem cells derived from the epiblast (EpiSCs) (Vallier, Mendjan et al. 
2009). Recent studies discovered the important role of BMP signaling in the initial stage 
of reprogramming. BMP7 enhances reprogramming efficiency by increasing the number 
of reprogrammed colonies after MEFs are transduced with OSKM (Samavarchi-Tehrani, 
Golipour et al. 2010). The production of iPSCs from mouse fibroblasts requires a 
mesenchymal-to-epithelial transition (MET). Small molecule inhibitors of TGF-β 
signaling facilitate MET, and therefore enhance reprogramming efficiency (Li, Liang et 
al. 2010).  
 
Selective small molecule TGF-β receptor inhibitors, including A83-01 (2), LY-
364947 (3), SB431542 (4), and 616452 (5) promote iPSC production preventing 
phosphorylation of intracellular SMAD proteins which is downstream of TGF-R (Figure 
2-2). The combination of A-83-01 and PD0325901 enhanced the reprogramming 
efficiency of human keratinocytes transduced with either OSKM or OSK. Neonatal 
human epidermal keratinocytes (NHEKs), transduced with just OK, and treated with A-
83-01 and PD0325901, still generated iPSCs, albeit with lower efficiency (Zhu, Li et al. 
2010). AMI-5, a protein arginine methyltransferase inhibitor, in combination with A83-
01, induced reprogramming of MEFs transduced with Oct4, and replaced Sox2 during 
mouse somatic cell reprogramming. The generated miPSCs displayed similar 
pluripotency characteristics to mESCs (Yuan, Wan et al. 2011). LY-364947 was 
discovered to replace Sox2 in miPSC generation (Ichida, Blanchard et al. 2009, Staerk, 
Lyssiotis et al. 2011). Furthermore, the compounds 616452 and SB431542 were able to 
substitute for Sox2 during miPSC and hiPSC generation (Ichida, Blanchard et al. 2009, 
Li, Zhou et al. 2009, Li, Zhang et al. 2011, Wang, Xu et al. 2011). Inhibition of TGF-β 
signaling leads to sustained transcription of Nanog, causing complete reprogramming 
(Attisano and Wrana 2002, Ichida, Blanchard et al. 2009). 
 
The simultaneous inhibition of the TGF-β and MAPK/ERK pathways using the 
small molecules SB431542 and PD0325901, in combination with OSKM, significantly 
enhances the reprogramming of human fibroblasts (Lin, Ambasudhan et al. 2009). 
Likewise, the dual inhibition of the TGF-β and MAPK/ERK pathways in combination 
with parnate, a small molecule inhibitor of lysine-specific demethylase 1, and  
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Figure 2-1. FGF/MAPK/ERK Signaling Pathway 
The binding of fibroblast growth factor (FGF) to the cell surface FGF receptor (FGFR) 
activates the tyrosine kinase activity of the cytoplasmic domain of the FGFR and induces 
a protein kinase cascade, resulting in the activation of MEK and subsequent activation of 
another mitogen-activated protein kinase (MAPK). Activated MAPK now has the ability 
to activate transcription factors in the nucleus. However, inhibition of MEK through 
chemical manipulation deactivates the MAPK/ERK signaling pathway, yet triggers 
somatic cell reprogramming. 
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Figure 2-2. TGF-β Signaling Pathway 
SMADs are transcription factors that are activated in response to an extracellular TGF-β 
ligand binding to membrane bound TGF-β receptors. SMAD then enters the nucleus to 
act as a transcription factor for various genes. TGF-β signaling plays an important role in 
reprogramming, and inhibitors of TGF-β receptors can enhance reprogramming by 
functionally replacing key transgenic transcription factors. 
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CHIR99021 (6), a GSK-3β small molecule inhibitor, promotes the reprogramming of 
human keratinocytes in the presence of Oct4 and Klf4 (Li, Zhou et al. 2009). 
  
Oct4-only reprogramming has been achieved with several human somatic cell 
types when used in combination with small molecules. Oct4 transduced neonatal human 
epidermal keratinocytes (NHEKs), treated with sodium butyrate (NaB), a histone 
deacetylase inhibitor, PS48, a small molecule activator of PDK1 (3′-phosphoinositide- 
dependent kinase-1), and A-83-01, a selective TGF-β receptor inhibitor, for four weeks, 
followed by continued treatment with NaB, PS48, A-83-01 and PD0325901 for another 
four weeks, in addition to treatment with parnate and CHIR99021, generated iPSCs from 
adult epidermal keratinocytes. The generated iPSCs demonstrated characteristics similar 
to pluripotent hESCs (Zhu, Li et al. 2010). The combination of small molecule inhibitors 
of two key signaling pathways increases the efficiency of reprogramming by replacing 
defined transcription factors.  
 
 
Wnt Signaling Pathway 
 
The Wnt signaling pathway has been shown to have roles in maintaining 
mESCs/hESCs pluripotency, in maintaining undifferentiated adult stem cells, and in 
promoting ESC self-renewal in various tissues. Wnt antagonists have also been shown to 
regulate hematopoietic stem cell fate decisions (Cain and Manilay 2013). Additionally, 
the activation of Wnt signaling in various types of cancer stem cells (CSCs) has been 
well researched (Reya and Clevers 2005), however the mechanism by which Wnt 
signaling regulates stem cell fate is not fully understood. Several Wnt inhibitors have 
been studied in pre-clinical trials that screened for compounds selectively toxic to cancer 
stem cells from breast cancers. The small molecule compound salinomycin, for example, 
induces epithelial differentiation of tumor stem cells and inhibits mammary tumor growth 
in vivo (Gupta, Onder et al. 2009) by preventing the phosphorylation of Wnt receptor, 
LPR6 (Lu, Choi et al. 2011). 
   
Activation of Wnt signaling sustains the expression of Oct4, Rex1, and Nanog by 
antagonizing GSK3-β, a part of the β-catenin destruction complex. GSK3-β antagonizing 
causes nuclear accumulation of β-catenin, an intracellular signaling molecule responsible 
for activation of reprogramming genes (Sato, Meijer et al. 2004, Ogawa, Nishinakamura 
et al. 2006, Singla, Schneider et al. 2006, Cai, Ye et al. 2007, Marson, Foreman et al. 
2008, Ho, Papp et al. 2013, Holland, Klaus et al. 2013). Lithium Chloride (LiCl) and 
CHIR99021 (CHIR), small molecule GSK3-β inhibitors, activate Wnt signaling (Figure 
2-3). LiCl promotes reprogramming efficiency of somatic cells into both miPSCs and 
hiPSCs. LiCl also acts as an epigenetic modulator by down-regulating LSD1, an H3K4-
specific demethylase (Wang, Xu et al. 2011). CHIR was reported to induce the 
reprogramming of both mouse and human somatic cells in the absence of Sox2 (Li, Zhou 
et al. 2009). CHIR was also reported to induce the reprogramming of MEFs transduced 
with only two transcription factors, Oct4 and Klf4. When used in combination with 
HDAC inhibitors valproic acid (VPA) and 616452, CHIR increased the reprogramming 
efficiency of MEFs transduced with Oct4 and Klf4 into miPSCs. Investigators even   
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Figure 2-3. Wnt Signaling Pathway 
The canonical Wnt pathway is activated by the binding of an extracellular Wnt-protein 
ligand to a trans-membrane Frizzled family receptor. β-catenin accumulates in the 
cytoplasm, translocates into the nucleus, and interacts with Tcf/Lef proteins to activate 
target genes. In the absence of Wnt stimulation, a destruction complex, including the 
protein glycogen synthase kinase 3-beta (GSK3-β) and adenomatosis polyposis coli 
(APC), degrades β-catenin by targeting it for ubiquitination. The Wnt signaling and       
β-catenin pathways secure the maintenance of self-renewal of mouse and human 
embryonic stem cells (mESCs, hESCs) through the inhibition of GSK3-β, and the 
subsequent nuclear accumulation of β-catenin. 
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reported the generation of miPSCs from Oct4-only transduced MEFs in combination with 
VPA, CHIR99021, and 616452; however, the efficiency rate was low (Li, Zhang et al. 
2011). Kenpaullone, has an established role as a GSK-3β or CDK inhibitor (Kenpaullone 
inhibits CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p25, and 
CDK5/cyclin/p35), and can replace Klf4 to generate miPSCs that are identical to mESCs 
(Lyssiotis, Foreman et al. 2009). 
  
Compound B6, (aurora kinase inhibitor) inhibits GSK3-β, and overall facilitates 
the reprogramming efficiency of somatic cells into miPSCs (Giorgetti, Montserrat et al. 
2010). Compounds B8, an inositol triphosphate 3-kinase inhibitor, and B10, a P38 kinase 
inhibitor, enhance the efficiency of reprogramming into miPSCs. When combined, 
Compounds B6, B8, and B10 have a synergistic effect on reprogramming efficiency (Li 
and Rana 2012). Compound B4, a TGFβ-RI/Activin-receptor-like kinase 4 (ALK-4) 
inhibitor, also promotes reprogramming. Compound B4 can also replace Sox2 when used 
in combination with a specific small molecule cocktail (Ichida, Blanchard et al. 2009, 
Maherali and Hochedlinger 2009, Li and Rana 2012). 
 
Olanzapine, a D2/5-HT2 antagonist, enhances the differentiation of neural stem 
cells (NSCs) to oligodendrocyte-like cells (ODLCs) through inhibition of the β-catenin 
pathway. Olanzapine has positive prospects for the treatment of glioblastomas since 
GSLCs share similar characteristics to NSCs (Guo, Yang et al. 2015).  Small molecules 
that target mediators of the Wnt signaling pathway, including the key mediator β-catenin, 
regulate the expression of target genes, influence cell fate, and overall enhance the 
efficiency of reprogramming. 
 
 
Sonic Hedgehog Homolog (SHH) Signaling Pathway 
 
The sonic hedgehog homolog signaling pathway plays a key role in regulating 
cellular reprogramming. The SHH pathway also helps to regulate the behaviors of cancer 
stem cells. The Smoothened protein (SMO) is a key component of the SHH pathway 
because it acts as a bridge between the Patched receptor (Ptch) and the intracellular Gli 
complex (Simeone 2008). When the Hh ligand binds to Patched, Smoothened is released 
and the SHH signaling pathway is activated. SMO antagonists, including Cyclopamine 
and vesmodigib (GDC-0449), inhibit the SHH signaling pathway by directly binding to 
Smoothened. Such small molecule compounds that target Smoothened have been 
reported to decrease the number of cancer stem cells and their growth. Cancer stem cells 
are a subpopulation of cancer cells within the tumor that have the ability to self-renew, 
proliferate, and differentiate. Inhibition of the SHH signaling pathway may therefore be 
beneficial for cancer treatment through the direct targeting of the cancer stem cell 
population (Merchant and Matsui 2010, Ailles and Siu 2011, Kelleher 2011, Perrot, 
Javelaud et al. 2013). Activation of the sonic hedgehog pathway has also been shown to 
lead to an intermediate cell type that expresses Sox2, Klf4, and c-Myc. The small 
molecule compounds, 25-hydroxycholesterol (25-OHChl) and purmorphamine (7) can 
reprogram mouse embryonic and adult fibroblasts into iPSCs in combination with Oct4 
(Moon, Heo et al. 2011) (Figure 2-4). Other components of the SHH pathway, including   
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Figure 2-4. Sonic Hedgehog Homolog (SHH) Signaling Pathway 
The Sonic hedgehog signaling pathway is stimulated when sonic hedgehog homolog 
(SHH) binds to the Patched (PTCH) receptor. In the absence of the SHH ligand, PTCH 
inhibits Smoothened (SMO), a G protein-coupled receptor (GPCR). SHH binding 
releases SMO inhibition, causing the activation of the GLI complex, a key regulator of 
the transcription of hedgehog target genes in the nucleus. Small molecule compounds that 
act as SMO agonists can activate the Sonic hedgehog signaling pathway and enhance 
somatic cell reprogramming. 
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targets upstream of SMO, the Shh ligand, and targets downstream of SMO, like Gli 
transcription factors, can be inhibited.  Although small molecule inhibitors exist for these 
targets, further investigation is required to determine their inhibitory effect on iPSC 
production. Potent small molecule modulators of the SHH pathway have been recently 
reviewed (Heretsch, Tzagkaroulaki et al. 2010). 
 
 
cAMP Signaling Pathway 
 
Activators of the cAMP signaling pathway can also induce cellular 
reprogramming. 2-methyl-5-hydroxytryptamine, a 2-Me-5HT; 5-HT3 agonist, Forskolin 
(FSK) (8), an adenylyl cyclase activator, and D4476 a casein kinase 1 inhibitor, can all 
act as chemical replacements for Oct4 in mouse cells (Hou, Li et al. 2013). Prostaglandin 
(9), an EP4 agonist, and Rolipram (10), a direct selective PDE4 inhibitor, promote late 
reprogramming in mouse cells (Hou, Li et al. 2013). 8-Bromoadenosine 3’’5’’-cyclic 
monophosphate (8-Br-cAMP) (11) is a cAMP-dependent protein kinase activator that 
promotes reprogramming into hiPSCs (Jung, Kim et al. 2014). The downstream effects of 
these small molecules are to increase cellular cAMP production (Figure 2-5). cAMP 
levels have also been reported to be regulated by ascorbic acid (AA). AA is a competitive 
inhibitor of adenylate cyclase and therefore lowers the intracellular concentration of 
cAMP (Rahman, Al Frouh et al. 2014).  Chemical modulation of the cAMP signaling 
pathway represents another fundamental mechanism controlling cellular reprogramming. 
 
 
Additional Signaling Pathway Small Molecule Modulators That Promote IPSC 
Production 
 
Additional mechanisms regulating reprogramming efficiency have been 
uncovered in multiple reports. Foremost, the inhibition of the mammalian target of 
rapamycin (mTOR) pathway by rapamycin, a mTOR inhibitor, enhances the 
reprogramming efficiency of somatic cells into miPSCs (Chen, Shen et al. 2011). 
TTNPB, a synthetic retinoic acid receptor ligand, also enhances reprogramming 
efficiency. Furthermore, when used in combination with other small molecule 
compounds, including VPA, CHIR, 616452, Parnate, DZNep, MEFs were successfully 
reprogrammed into miPSCs using TTNPB (Hou, Li et al. 2013). Fructose 2,6-
bisphosphate, a phosphofructokinase 1 activator, and N-oxaloylglycine, a prolyl-4-
hydroxylase inhibitor, can enhance the reprogramming efficiency to hiPSC when used in 
combination with OSKM (Zhu, Li et al. 2010). Inhibitors of Src family tyrosine kinase 
including, Dasatinib, iPY razine (iPY), and PP1 can replace Sox2 during cellular 
reprogramming of MEFs into miPSCs (Staerk, Lyssiotis et al. 2011). The combination of 
BayK (a L-channel calcium agonist) and BIX01294 can replace Sox2 during the 
reprogramming of MEFs transduced with Oct4 and Klf4, into miPSCs (Shi, Desponts et 
al. 2008).  
 
Interestingly, mechanistic studies have suggested that the modulation of cell 
metabolism from mitochondrial oxidation to glycolysis is an important factor during   
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Figure 2-5. cAMP Signaling Pathway 
Adenylyl cyclase is a 12-transmembrane glycoprotein that catalyzes the conversion of 
adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). cAMP is 
an activator of protein kinase A (PKA), and this enzyme helps regulate gene expression. 
Phosphodiesterase (PDE4) is an enzyme that degrades cAMP to adenosine 
monophosphate (AMP), thereby inactivating PKA. Prostaglandin E2 is an agonist for 
EP4, a prostaglandin receptor. Chemical modulators of the cAMP signaling pathway can 
increase cellular cAMP levels and enhance somatic cell reprogramming. 
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cellular reprogramming. DNP (2,4-dinitrophenol) modulates mitochondrial oxidation by 
inhibiting ATP phosphorylation. The combination of Oct4 expression and DNP was 
reported to enhance reprogramming efficiency of human primary somatic cells into 
iPSCs. Quercetin, a hypoxia-inducible factor (HIF) pathway activator, has been used to 
promote the reprogramming of human somatic cells to pluripotent stem cells by 
promoting glycolytic metabolism. However quercetin has multiple other targets and the 
mechanism of affecting reprogramming may be more complicated. The small molecule 
PS48, a PDK1 activator that leads to activation of AKT, has been suggested to work in a 
similar fashion. Collectively, these findings suggest that a metabolic switch to anaerobic 
glycolysis is a key step during iPSC reprogramming (Zhu, Li et al. 2010). The breadth of 
regulatory pathways required for efficient cellular reprogramming is supported by the 
scope of small molecule compounds being discovered. Chemical modulation of key 
regulatory pathways evidently represents a key step towards the ultimate goal of chemical 
reprogramming, however, epigenetic modulations is another fundamental tool for 
efficient cellular reprogramming. 
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CHAPTER 3.    SMALL MOLECULE EPIGENETIC MODULATING 
COMPOUNDS THAT FACILIATE REPROGRAMMING EFFICIENCY DURING 
IPSC PRODUCTION 
 
 
Transient expression of the four specific transcription factors, OSKM, modifies 
chromatin structure and causes cellular plasticity to direct the reprogramming of 
fibroblasts to somatic cells (Efe, Hilcove et al. 2011, Kim, Efe et al. 2011). However, 
expression of a combination of OSKM, small molecules, and additional factors has not 
proven sufficient for complete pluripotency. Therefore, additional requirements are 
needed to overcome major epigenetic barriers that prevent cellular reprogramming 
(Hanna, Saha et al. 2009, Smith, Nachman et al. 2010). 
 
Indeed, chromatin-modifying enzymes can be utilized to more efficiently generate 
iPSCs with fewer transcription factors. Several small molecules enhance the 
reprogramming of somatic cells into iPSCs by inhibiting epigenetic modifying enzymes, 
including DNA methyltransferases (DNMTs), histone methyltransferases (HMT), histone 
deacetylases (HDAC), and histone demethylases (HDM) (Figure 3-1). These small 
molecules, termed epigenetic modulating compounds, act as potent enhancers of iPSC 
generation in a target-specific manner. They modify chromatin structure causing 
subsequent changes to the epigenome. Chromatin remodeling is key for efficient 
reprogramming and has recently been reviewed (Plath and Lowry 2011). In order to 
generate fully reprogrammed colonies, changes in DNA methylation must occur in 
addition to structural changes allowing chromatin to be more accessible to transcriptional 
machinery. Indeed, DNA methylation has a significant role in maintaining epigenetic 
states (Mikkelsen, Hanna et al. 2008, Sridharan, Tchieu et al. 2009). 
 
 
DNA Methyltransferase (DNMT) Inhibitors 
 
Pluripotent stem cells have a less methylated epigenetic profile compared to 
somatic cells. Therefore, inhibition of DNMTs may enhance cellular reprogramming by 
reactivating the expression of previously repressed genes. 5-Azacytidine (5-aza-CR, 
AZA) (15) is a DNA demethylating agent that was first utilized in cellular 
reprogramming to convert fibroblasts into muscle cells (Taylor and Jones 1979). AZA 
was more recently shown to increase cellular plasticity and overall efficiency of cellular 
reprogramming of mouse fibroblasts and B lymphocytes into iPSCs. Indeed, AZA 
treatment caused a 4-fold increase in the number of ESC-like colonies (Mikkelsen, Hanna 
et al. 2008). More recently, AZA treatment of partially reprogrammed cells induced a 
stable transition to fully reprogrammed iPSCs (Papp and Plath 2013). RG108 (16), like 
AZA, is an inhibitor of DNMT enzymatic activity and has been shown to enhance the 
reprogramming efficiency of cells transduced with Oct4/Klf4 (in the absence of Sox2) 
(Li, Zhou et al. 2009). However, despite the effects of DNA methylation inhibitors, their 
mechanisms of action require further investigation. 
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Figure 3-1. Small Molecule Epigenetic Compounds 
Several small molecule inhibitors of epigenetic modifying enzymes, such as DNA 
methyltransferase (DNMT), histone deacetylase (HDAC), histone methyltransferase 
(HMT), and histone demethylase (HDM), modify chromatin structure to allow changes in 
the epigenome during reprogramming of somatic cells into iPSCs. DNMTs are enzymes 
that catalyze the transfer of one methyl group to DNA. Chemical inhibition of DNMTs 
may facilitate cellular reprogramming by re-expressing genes previously repressed by 
DNA methylation. Histone methylation also plays a key role in epigenetic gene 
regulation. HDACs are enzymes that remove acetyl groups from histones, allowing the 
histones to wrap DNA more tightly. HMTs are histone-modifying enzymes that catalyze 
the transfer of one, two, or three, methyl groups to lysine and arginine residues of histone 
proteins. HDMs are enzymes that remove methyl groups from histones. HDMs play an 
important role in epigenetic modification mechanisms because they control the 
methylation level that occurs on DNA and histones, and therefore regulate the chromatin 
state. 
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Histone Methyltransferase (HMT) Inhibitor 
 
The small molecule, BIX-01294 (BIX) (19) is an inhibitor of the G9a histone 
methyltransferase (G9a HMTase) (Kubicek, O'Sullivan et al. 2007). miPSCs generated 
from neural progenitor cells (NPCs) transduced with Oct4 and Klf4 and treated with BIX, 
exhibited similar characteristics to miPSCs generated using the four distinct transcription 
factors. This single small molecule compound could functionally replace c-Myc and 
Sox2. It was simultaneously reported that fetal NPCs virally transduced with Klf4, Sox2, 
and c-Myc, in combination with BIX treatment, generated iPSCs, at a low frequency 
however. Indeed, BIX may facilitate the active transcription of Oct4, as previous findings 
postulated (Shi, Do et al. 2008). 
 
The knockdown of SUV39h1, a histone methyltransferase, has been shown to 
enhance reprogramming. This study also reported that the knockdown of DOT1L, a 
H3K79 histone methyltransferase, increased reprogramming efficiency and the number of 
iPSC colonies, and could functionally replace Klf4 and c-Myc. The DOL1L inhibitor, 
EPZ004777, was reported to selectively inhibit H3K79 methylation in mixed lineage 
leukemia cells and block the expression of leukemogenic genes. The expression of Nanog 
and Lin28, two factors that play important functional roles in the promotion of 
reprogramming, was reported to increase when used in conjunction with the Dot1L 
inhibitor during early reprogramming (Daigle, Olhava et al. 2011, Onder, Kara et al. 
2012). 
 
In combination with BIX, RG108 was reported to promote the reprogramming of 
MEFs transduced with Oct4 and Klf4 (Shi, Desponts et al. 2008, Li and Ding 2010). 
During the cellular reprogramming of mouse skeletal muscle cells into miPSCs, RG108 
substituted for Oct4 when skeletal muscle cells endogenously expressed Sox2, Klf4, and 
c-Myc (Wang, Xu et al. 2011). More importantly, RG108 has been shown to enhance the 
reprogramming efficiency of human cells transduced with Oct4 and Klf4 (in the absence 
of Sox2) (Li, Zhou et al. 2009). RSC133 (17) is a small molecule compound that inhibits 
both histone deacetylase and DNA methyltransferase. By doing so, RSC133 enhanced the 
reprogramming of human somatic cells into iPSCs and sustained pluripotency in hiPSCs 
(Lee, Xia et al. 2012). During cellular reprogramming, epigenetic modulators modify 
chromatin structure by making it more open to changes in the epigenome and 
subsequently controlling cell fate.  
 
 
Histone Deacetylase (HDAC) Inhibitors 
 
Histone deacetylases (HDACs) represent a class of enzymes that can remove 
acetyl groups from histones causing DNA to tightly wrap around histones resulting in 
decreased gene expression. HDACs also exhibit non-histone functions. Histone 
acetyltransferases oppose HDAC enzymatic activity by acetylating histones, causing a 
loosening of the histone/DNA interaction resulting in increased gene expression. Small 
molecule HDAC inhibitors have been extensively studied to better understand their 
selectivity since some HDAC isoforms are associated with cellular functions in multiple 
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diseases (Itoh, Suzuki et al. 2008, Bradner, West et al. 2010). Sodium butyrate (NaB) is a 
cell permeable small molecule HDAC inhibitor and was reported to enhance the 
reprogramming efficiency (15- to 51-fold increase) of human adult or fetal fibroblasts 
into iPSCs through either retroviral or piggyBac transposon vectors expressing 4 to 5 
reprogramming genes. In the absence of either Klf4 or c-Myc, sodium butyrate exhibited 
an even greater increase in reprogramming efficiency (>100- to 200-fold increase). The 
generated iPSCs reportedly expressed normal karyotypes and pluripotency. Treatment 
with sodium butyrate also enhanced histone H3 acetylation, promoter DNA 
demethylation, and the expression of endogenous pluripotency genes, including DPPA2 
(Mali, Chou et al. 2010). 
 
VPA (12) is a second HDAC inhibitor that enhances reprogramming efficiency by 
more than 100-fold and promotes cellular reprogramming in combination with Oct4, 
Sox2, and Klf4 (Huangfu, Maehr et al. 2008). VPA, in combination with three other 
small molecules, including, tranylcypromine (H3K4 demethylation inhibitor), 
CHIR99021 (GSK3-β inhibitor) and 616452 (VC6T) (TGF-β signaling inhibitor), 
induced the reprogramming of mouse fibroblasts in the presence of Oct4 (Li, Zhang et al. 
2011). Three known HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) (14), 
trichostatin A (TSA) (13) and VPA were reported to improve reprogramming efficiency 
(Huangfu, Maehr et al. 2008). SAHA-PIP (SAHA is a histone deacetylase inhibitor and 
PIP is a sequence-specific DNA binding pyrrole-imidazole polyamide for modulating 
specific gene networks) targets and activates the Oct3/4 regulatory pluripotency genes in 
human dermal fibroblasts (Pandian, Sato et al. 2014). Small molecule compounds that 
modulate epigenetic enzymes, including HDAC inhibitors, can improve reprogramming 
efficiency or functionally replace reprogramming transcription factors. 
 
 
Histone Demethylase (HDM) Inhibitor 
 
Tranylcypromine (Parnate) (18) is an H3K4 demethylation inhibitor that enhances 
the reprogramming of mouse somatic cells into miPSCs by 20-fold (Li, Zhang et al. 
2011). Tranylcypromine treatment in mouse embryonic carcinoma cells was reported to 
activate endogenous Oct4 expression (Lee, Wynder et al. 2006). When CHIR99021 was 
combined with Parnate, CHIR99021 induced the reprogramming of human primary 
keratinocytes in the presence of Oct4 and Klf4 (Li, Zhou et al. 2009). DZNep                
(3-deazaneplanocin A) is another small molecule epigenetic modulator. When DZNep 
was added in the late phase of chemical reprogramming, Oct4 expression was 
significantly elevated. DZNep also significantly decreased DNA and H3K9 methylation 
at the Oct4 promoter, which may explain its role in Oct4 activation (Feldman, Gerson et 
al. 2006, Chen, Liu et al. 2013, Hou, Li et al. 2013). Histone H3 lysine 9 (H3K9) 
methylation (histone lysine methylation) is a determining factor for the pre-iPSC state, 
and its eradication was reported to lead to fully reprogrammed iPSCs (Chen, Liu et al. 
2013). H3K9me3 inhibition can increase reprogramming efficiency because larger 
regions of H3K9me3 are present in differentiated cells that have to be replaced with open 
chromatin in pluripotent cells (You and Han 2014). The removal of H3K9me3 serves as 
an epigenetic barrier in order to complete reprogramming and additional inhibitors should 
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be investigated. Future studies should investigate other direct small molecule modulators 
of the epigenetic state in order to improve mouse and human somatic cell 
reprogramming. Remodeling of the epigenome is an integral step in cellular 
reprogramming. Epigenetic modifications facilitate cellular reprogramming by making 
cells more permissive to these epigenenomic changes. Consistent with this notion, 
compounds that modulate epigenetic enzymes, including HDAC, HMT, HDM, and 
DNMT, can improve reprogramming efficiency or replace specific transcription factors. 
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CHAPTER 4.    CONCLUSION 
 
 
The production of induced pluripotent stem cells requires both lineage-specific 
transcription factors and a remodeled epigenetic landscape. Key drivers of the somatic 
state must efficiently be silenced in order for induction of pluripotency (Mikkelsen, 
Hanna et al. 2008, Pereira, Piccolo et al. 2010). Preliminary achievements of cellular 
reprogramming have enabled the generation of iPSCs from somatic cells by defined 
genetic factors. Interestingly, ESRRB, LIN28, DPPA2 and SALL4, are additional 
downstream factors that were shown to induce iPSCs from MEFs (Buganim, Faddah et 
al. 2012). However, genetic approaches to cellular reprogramming have concerns 
regarding safety and efficiency and additional barriers to the reprogramming process 
exist. 
 
Small molecules have offered a complementary approach and chemically induced 
pluripotent stem cell technology has attracted enormous interest for its potential 
application in regenerative medicine. To date, Sodium butyrate, VPA, CHIR99021, LiCl, 
616452, SB431542, PD325901, N-oxaloylglycine, PS48, 8-Br-cAMP, fructose 2,6-
bisphosphate, quercetin, and 2,4-dinitrophenol are all small molecule compounds used in 
hiPSC generation, but additional studies could examine whether other small molecules 
used in miPSC reprogramming are effective in hiPSC reprogramming. There is clear 
evidence that the modulation of key signaling pathways involved in iPSC induction, 
through the use of small molecules, improves reprogramming efficiency and iPSC 
quality, but the interplay between the signaling pathways requires better characterization 
for future clinical application. The investigation of small molecule compounds that 
promote cell cycle modifications is another promising avenue to investigate to lower 
reprogramming barriers and promote cellular reprogramming (Shi, Desponts et al. 2008, 
Hanna, Saha et al. 2009, Ruiz, Panopoulos et al. 2011). Indeed, the generation of 
chemically induced pluripotent stem cells has contributed to the area of stem cell research 
by influencing the direct reprogramming into functionally desirable cell types for clinical 
use. 
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